Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma
NCT ID: NCT01960634
Last Updated: 2015-05-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
58 participants
OBSERVATIONAL
2013-04-30
2015-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Samples: Blood from patients with BRAFV600 metastatic melanoma collected following standard medical practice.
The treatment is not the aim of the study. Patients can be treated either with specific or no-specific drug.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma
NCT02663232
An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma
NCT02143999
Utility of Novel BRAF Test for Melanoma
NCT01840527
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
NCT04759846
Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
NCT02416232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed Informed Consent Form
* Unresectable phase III or phase IV melanoma
* The patients should be starting a treatment for melanoma (either first line or subsequent lines)
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Grupo Español Multidisciplinar de Melanoma
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
María González Cao, MD
Role: STUDY_DIRECTOR
Hospital Universitario Quirón Dexeus
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Infanta Cristina
Madrid, Badajoz, Spain
Hospital Germans Trias i Pujol
Badalona, Barcelona, Spain
Hospital del Mar
Barcelona, Barcelona, Spain
Hospital Universitario Quirón Dexeus
Barcelona, Barcelona, Spain
Hospital Vall d'Hebron
Barcelona, Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, Spain
Hospital Marques de Valdecilla
Santander, Cantabria, Spain
Hospital Insular de Gran Canaria
Las Palmas de Gran Canaria, Las Palmas, Spain
Hospital Ramón y Cajal
Madrid, Madrid, Spain
Hospital Costa del SOl
Marbella, Málaga, Spain
Hospital Virgen de la Salud
Toledo, Toledo, Spain
Fundación Instituto Valenciano de Oncología
Valencia, Valencia, Spain
Hospital Miguel Servet
Zaragoza, Zaragoza, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GEM-1304
Identifier Type: OTHER
Identifier Source: secondary_id
GEM-1304
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.